Health Care • Other Pharmaceuticals
$0.31 ▲ +0.03
(+10.96%)
MKT CAP: $27.9M • VOL: 2.11M
52W L $0 52W H $1
COSM // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $65.3M | $54.4M | $53.4M |
| YoY Revenue Growth % | +19.9% | +2.0% | — |
| Gross Profit | $7.9M | $4.3M | — |
| Gross Margin % | 12.1% | 7.9% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$16.7M | -$15.5M | -$21.8M |
| Operating Margin % | -25.6% | -28.6% | -40.9% |
| Net Income (GAAP) | -$19.1M | -$16.2M | -$18.5M |
| EBITDA (Normalized) | -$16.7M | -$15.2M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$8.4M | -$7.7M | -$15.6M |
| Capital Expenditures (CapEx) | $55.7K | $418.1K | — |
| Free Cash Flow (FCF) | -$8.5M | -$8.1M | -$15.6M |
| FCF Margin % | -13.0% | -14.9% | -29.3% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $715.7K | $315.1K | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $18.4M | $24.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR COSM.